Home Home Contact Us Help Registering and Participating Disclaimer Please Note: THIS FORUM IS PATIENT MODERATED AND IS NOT CONNECTED TO ANY CLINIC OR DOCTOR. IF YOU WISH TO CONTACT A CERTAIN DOCTOR OR CLINIC, PLEASE LOOK IN THE ASK THE DOCTOR SECTION FOR DOCTOR OR CLINIC PHONE NUMBERS AND EMAIL ADDRESSES.

                       Home || Contact Us || Help Registering and Participating || Disclaimer

Unlock Secrets in Your Own DNA with 23andMe.com

Nutri-Health Products

 Buy 1 Get 1 Free at Puritan's Pride

LivLong – The Ultimate Anti-aging Product

SeaChange Partners with Life Extension Products

 

Barbara and Jeannine's Book

Bea Luis Memorial

 

Join the ICMS


Go Back   Stem Cell Pioneers > Diseases / Stem Cell Treatments > Other Issues and Diseases also treated with Stem Cells
Register Blogs FAQ Members List Social Groups Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old 05-10-2012, 05:39 AM
pink7 pink7 is offline
Senior Member
 
Join Date: Dec 2008
Location: Australia
Posts: 143
Default Pluristem stem cells saves Girl

This is such a happy outcome for this girl with Aplastic Anemia.

Pluristem stem cells save girl's life
Prof. Or: The results of this unique case indicate that PLX cells may be effective in treating other diseases that affect the bone marrow.
9 May 12 15:53, Globes correspondent
inShare3

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR)has announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating has seen a reversal of her condition. The improvement came due to a significant increase in her red cells, white cells and platelets following the intramuscular injection of Pluristem's PLacental eXpanded (PLX) cells. Aplastic bone marrow is a disease where the patient has no blood-forming hematopoietic stem cells in the bone marrow.

Hadassah Medical Center Bone Marrow Transplantation, Cell Therapy and Transplantation Research Center director Prof. Reuven Or said, "With her body rejecting all possible treatment, and with no other options, we finally turned to Pluristem's PLX cells, which literally saved her life. The results of this unique case indicate that PLX cells may be effective in treating other diseases that affect the bone marrow."

The patient has been hospitalized at the Hadassah Hebrew University Medical Center in Jerusalem since August 2011. Her aplastic bone marrow had been refractory to treatment. So she underwent allogeneic stem cell transplantation from a matched unrelated donor. The first transplant was unsuccessful and the patient remained with bone marrow failure. The patient underwent a second allogeneic stem cell transplantation from a second donor. The bone marrow function was very poor and the patient suffered from recurrent infections.

Two months after the patient's second bone marrow transplant, the child received PLX cells intramuscularly in two doses about one week apart. Some 10 days after the last administration of PLX cells, the patient's hematological parameters began to significantly increase, an effect that has persisted to date. The patient's general clinical status has also improved. Subsequent analysis has indicated that the PLX cells worked by stimulating the recovery of the hematopoietic stem cells contained in the second bone marrow transplant that she had received over two months earlier. Finally, after nine months of hospitalization, the child will be discharged from the hospital.

Pluristem chairman and CEO Zami Alberman said, "Pluristem is extremely happy that our PLX cells have helped this little girl. Remarkably, these beneficial effects were seen in the patient after our PLX cells were administered intramuscularly and correlate with the positive effects on the bone marrow when we administered our PLX cells intramuscularly (IM) in animals exposed to toxic levels of radiation. Pluristem now has several data points to indicate that our PLX cells may work for systemic diseases when given locally, away from the target organ, and without a need to give cells intravenously."

In February 2012, Pluristem announced the results of animal studies suggesting PLX cells can be potentially effective in treating the life threatening hematopoietic complications associated with Acute Radiation Syndrome (ARS). In these experiments, animals given PLX cells IM up to 24 hours post irradiation demonstrated a recovery of their red cells, white cells, platelets and bone marrow to almost normal levels. It was that announcement, and the significant deterioration of the patient following two bone marrow transplants, that led Prof. Or to contact Pluristem about the possible compassionate use of PLX cells to treat his young patient.

Pluristem recently received US FDA clearance to begin a Phase II clinical trial using the company's proprietary PLX-PAD cell product candidate intramuscularly for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD).

Published by Globes, Israel business news - www.globes-online.com - on May 9, 2012
Reply With Quote
  #2  
Old 05-10-2012, 12:25 PM
barbara barbara is offline
Pioneer Founding member
 
Join Date: May 2007
Posts: 6,892
Blog Entries: 5
Default

Pink7 - Thanks for posting this. What a great start to the day to read something like this.
__________________
First treatment in 2007. Pioneering ever since.

Barbara
Reply With Quote
Reply

Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

Copyright 2007 - 2011 Stem Cell Pioneers


All times are GMT -6. The time now is 09:53 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2013, vBulletin Solutions, Inc.
Stem Cell Pioneers